Drug Trial Radar · NCT04891198
ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
126
Planned (sponsor's estimate)
Start
Aug 6, 2021
Primary completion
Aug 30, 2027
Study completion Apr 30, 2028
Sponsor
- Lead sponsor
- 3D Medicines (Sichuan) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open, single-arm, multi-center Phase II clinical study of ENVAFOLIMAB single-agent treatment in patients with advanced solid tumors,to compare the overall response rate of TMB-high and TMB-Low,to determine the cut off value between TMB-high and TMB-Low of diagnosis device.Then,observe the efficacy of ENVAFOLIMAB uesd comfirmed TMB-H Value
Conditions
- Solid Tumor
Interventions
EnvafolimabDrug
Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: up to approximately half past one year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.